Atherothrombosis is the most frequent lesion substrate for cardiovascular complications and the leading cause of mortality in Spain. One of the biggest challenges in this area of research is to identify biomarkers that can predict cardiovascular events, and define key molecules in atherothrombosis development, in order to develop new safer and more effective therapeutic strategies.

In recent years we have launched several research projects, both clinical and experimental, focused on the study of the most relevant inflammatory, prothrombotic and proteolytic factors in the atherothrombotic process.

Our group includes basic and clinical scientists, and has a marked translational orientation based on knowledge. Therefore, we combine molecular biology, biochemical assays and cellular studies, with preclinical and clinical experimental approaches, to define the molecular mechanisms that regulate the progression and rupture of atherosclerotic plaque and thrombosis, and determine its potential as biomarkers and therapeutic targets. The main objective is to prevent and treat the vascular pathological processes that lead to thrombosis and the clinical ischemic event.

The most recent research activity of the group has allowed the identification of possible targets, both in thrombosis and in vascular remodeling, that may be useful as biomarkers in subclinical and clinical atherosclerosis, and their association with severity and a worse prognosis.

The design and synthesis of new series of small molecules capable of modifying the expression of these possible targets has allowed us to analyze their efficacy in the prevention of thrombosis and control of haemorrhage in vitro and in vivo, having patents for their possible clinical use.

Currently, the main research areas are:

• Identification of new therapeutic targets and prognostic markers involved in the development of thrombotic events in patients with cardiovascular diseases, by studying the transcriptome of circulating extracellular vesicles (EVs).

• Study of thrombus components that condition a poor recanalization response in ischemic stroke and identification of effective and safe strategies that allow the selection of patients who can benefit from thrombolysis or endovascular treatment.

• Genomic analysis of somatic mutations related with aging (CHIP) and its association with thrombotic risk to establish new targets aimed at preventing and treating patients with thrombosis (personalized medicine).

Fecha de actualización: Noviembre 2018

"We've carried out clinical trials in patients with clinical and subclinical atherosclerosis, which suggest that MMP-10 may be a biomarker for vascular risk", Dra. Josune Orbe, Principal Investigator .


Nerea Cano
Avda. Pío XII, 55
31008 Pamplona

(+34) 948 194 700 Ext. 3044